Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: Effect of polymers and efflux transporters

Expert Opinion on Drug Delivery

Volumn 11, Issue 4, 2014, Pages 479-492

  Bandyopadhyay, Shantanu ^a,b   Katare, Op ^a   Singh, Bhupinder ^a  

^a PANJAB UNIVERSITY   (India)

^b Affiliated to Uttarakhand Technical University   (India)

Author keywords

Lipid lowering; Polymeric precipitation inhibitor; Precipitation; Self nanoemulsifying drug delivery system; Single pass intestinal perfusion

Indexed keywords

EZETIMIBE; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; BRIGHT FIELD MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INTESTINE PERFUSION; LIPID BLOOD LEVEL; MICROSCOPY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRECIPITATION; PROCESS OPTIMIZATION; RAT; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; FEMALE; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; INTESTINE, SMALL; LIPIDS; NANOPARTICLES; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; X-RAY DIFFRACTION;

EID: 84897877992     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.877885     Document Type: Article

References (64)

1. Farnier M. Ezetimibe in hypercholesterolaemia. Int J Clin Pract 2002;56(8):611-14 Available from: http://www.drugbank.ca/drugs/APRD00619 [Accessed 15 May 2011]
2. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin Vasc Med 2004;4(1):43-50
3. Lutjohann D, von Bergmann K, Sirah W, et al. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract 2008;62(10):1499-510
4. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44(5):467-94
5. Oswald S, Haenisch S, Fricke C, et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006;79(3):206-17
6. Simard C, Turgeon J. The pharmacokinetics of ezetimibe. Can J Clin Pharmacol 2003;10(Suppl A):13A-20A
7. Patel R, Bhimani D, Patel J, Patel D. Solid-state characterization and dissolution properties of ezetimibe-cyclodextrins inclusion complexes. J Incl Phenom Macrocycl Chem 2008;60:241-51
8. Parmar KR, Shah SR, Sheth NR. Studies in dissolution enhancement of ezetimibe by solid dispersions in combination with a surface adsorbent. Dissociation Technol 2011;8:55-61
9. Sancheti PP, Karekar P, Vyas VM, et al. Preparation and physicochemical characterization of surfactant based solid dispersions of ezetimibe. Pharmazie 2009;64(4):227-31
10. Mulye SP, Jamadar SA, Karekar PS, et al. Improvement in physicochemical properties of ezetimibe using a crystal engineering technique. Powder Technol 2012;222:131-8
11. Gulsun T, Gursoy RN, Oner L. Design and characterization of nanocrystal formulations containing ezetimibe. Chem Pharm Bull (Tokyo) 2011;59(1):41-5
12. Pandya V, Patel J. Formulation and evaluations of ezetimibe nanoparticles prepared by controlled nanoprecipitation and transformation into solid dosage form. Acta Pharm Sci 2011;53:477-88
13. Khanfar M, Sheikh Salem M, Hawari R. Formulation factors affecting the release of ezetimibe from different liquisolid compacts. Pharm Dev Technol 2013;18(2):417-27
14. Kiekens F, Eelen S, Verheyden L, et al. Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci 2012;101(3):1136-44
15. Bali V, Ali M, Ali J. Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. J Drug Target 2010;18(7):506-19
16. Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces 2010;76(2):410-20
17. Bali V, Ali M, Ali J. Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Int J Pharm 2011;403(1-2):46-56
18. Khan AW, Kotta S, Ansari SH, et al. Potentials and challenges in selfnanoemulsifying drug delivery systems. Expert Opin Drug Deliv 2012;9(10):1305-17
19. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (Lond) 2010;5(10):1595-616
20. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48
21. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci 2008;35(3):183-92
22. Dabhi MR, Limbani MD, Sheth NR. Preparation and in vivo evaluation of self-nanoemulsifying drug delivery system (SNEDDS) containing ezetimibe. Curr Nano 2011;7:616-27
23. Cuine JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 2008;97(2):995-1012
24. Cuine JF, Charman WN, Pouton CW, et al. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res 2007;24(4):748-57
25. Gao P, Morozowich W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Deliv 2006;3(1):97-110
26. Singh B, Bandopadhyay S, Kapil R, et al. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 2009;26(5):427-521
27. Bandyopadhyay S, Katare OP, Singh B. Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces 2012;100:50-61
28. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm 1995;114(1):103-10
29. Laia CAT, Lopez-Cornejo P, Costa SMB, et al. Dynamic light scattering study of AOT microemulsions with nonaqueous polar additives in an oil continuous phase. Langmuir 1998;14(13):3531-7
30. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22(3):659-61
31. ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A(R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2003
32. Gao P, Akrami A, Alvarez F, et al. Characterization and optimization of AMG 517 supersaturatable selfemulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 2009;98(2):516-28
33. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009;98(8):2549-72
34. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th edition. Pharmaceutical Press, London; 2009
35. Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated selfnanoemulsifying drug delivery systems (super-SNEDDS). J Control Release 2012;160(1):25-32
36. Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003;92(12):2386-98
37. Wei Y, Ye X, Shang X, et al. Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS). Colloids Surf A Physicochem Eng Aspects 2012;396:22-8
38. Raghavan SL, Kiepfer B, Davis AF, et al. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001;221(1-2):95-105
39. Chen Y, Chen C, Zheng J, et al. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull 2011;34(2):278-86
40. Khanfar M, Sheikh Salem M, Hawari R. Formulation factors affecting the release of ezetimibe from different liquisolid compacts. Pharm Dev Technol 2012. [Epub ahead of print]
41. Gao P, Guyton ME, Huang T, et al. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 2004;30(2):221-9
42. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm 2000;193(2):231-7
43. McClements DJ. Food emulsions. Principles, practice and techniques. CRC Press; Boca Raton, USA: 1999
44. Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003;23(11):1463-74
45. Maki KC, Davidson MH, Malik KC, et al. Cholesterol lowering with highviscosity hydroxypropylmethylcellulose. Am J Cardiol 1999;84(10):1198-203
46. Reppas C, Meyer JH, Sirois PJ, Dressman JB. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroenterology 1991;100(5 Pt 1):1217-23
47. Reppas C, Swidan SZ, Tobey SW, et al. Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly hypercholesterolemic human subjects. Eur J Clin Nutr 2009;63(1):71-7
48. van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134(2):409-17
49. Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992;9(1):87-93
50. Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106(1):15-23
51. Jeong EJ, Liu Y, Lin H, Hu M. In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, editors. Optimization in drug discovery. 1st edition. Humana Press, Inc; New York; 2004. p. 65-76
52. Madan J, Chawla G, Arora V, et al. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 2005;7(1):E224-30
53. Oh DM, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res 1993;10(2):264-70
54. Lennernas H. Human intestinal permeability. J Pharm Sci 1998;87(4):403-10
55. Johnson DA, Amidon GL. Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol 1988;131:93-106
56. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50(1-2):61-80
57. Yamada A, Maeda K, Kamiyama E, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 2007;35(12):2166-76
58. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 2009;37(10):2028-36
59. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297(2):G371-7
60. Tucker TG, Milne AM, Fournel-Gigleux S, et al. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 2012;83(2):279-85
61. Yokooji T, Murakami T, Yumoto R, et al. Function of multidrug resistanceassociated protein 2 in acute hepatic failure rats. Eur J Pharmacol 2006;546(1-3):152-60
62. Li L, Yi T, Lam CW. Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in selfemulsifying drug delivery systems (SEDDS). Int J Pharm 2013;447(1-2):192-8
63. Chen Y, Li G, Wu X, et al. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol Pharm Bull 2008;31(1):118-25
64. Sun M, Zhai X, Xue K, et al. Intestinal absorption and intestinal lymphatic transport of sirolimus from selfmicroemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur J Pharm Sci 2011;43(3):132-40